GE expands partnership with Aussies on ultrasound disinfection

GE is pouring $7.5 million into an Australian company, Nanosonics, to push along the latter’s development and distribution of a disinfecting system for ultrasound transducers called Trophon EPR.

The investment follows six years after GE Healthcare began working with Nanosonics on the product, which won the FDA’s approval for U.S. sales in 2011. According to a joint news release, Trophon EPR is already in use at more than 800 sites around the world.

Noting that the global market for patient safety and infection control is at $10.3 billion and growing fast, the company said it will position Trophon EPR to complement its line of ultrasound technologies, software and services while also enabling it to extend its sales footprint to include Japan.

GE said it is making the investment through its Healthymagination Fund, which it launched in 2009 with a $6 billion pledge to support innovation in healthcare.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.